# Rat Adipose derived stem cell (rASC) adhesion and viability on non-cross-linked porcine acellular dermal matrix (ncl-PADM) in vitro

<u>Tejaswi S Iyyanki B.Tech</u>, Kristin T Campbell M.D, Lina Wang Ph.D, Anshu B Mathur Ph.D., Charles E Butler M.D. The University of Texas, MD Anderson Cancer Center, Department of Plastic Surgery, Houston, TX 77230, U.S.A.

#### **Statement of Purpose:**

Previous work in our lab with non-cross-linked porcine acellular dermal matrix (ncl-PADM) demonstrates its excellent clinical utility in reconstructive surgery<sup>1, 2</sup>. Additionally, we recently showed that adipose tissue derived stem cells (ASCs) increased cellular infiltration, revascularization, and remodeling of ncl-PADM ventral hernia repairs *in vivo* <sup>3</sup>. In this study, we report the viability, adhesion, and proliferation of ASCs onto ncl-PADM *in vitro*.

## Methods:


Subcutaneous fat tissue was harvested from syngeneic Brown Norway rats. ASCs were cultured in polystyrene flasks with  $\alpha$ -minimum essential medium containing 20% fetal bovine serum (FBS), 2mM L-glutamine, 100µg /ml penicillin and 100 µg/mL streptomycin and incubated at 37°C, 5% CO<sub>2</sub>, and 90% humidity. To determine the fraction of stem cell population in the cultured ASC's, cells were labeled with antibodies including CD 29, CD 44, CD 90, CD 31, CD 45 and P4HB (prolyl 4hydroxylase) and analyzed with fluorescence activated cell sorting (FACS). FACS data analysis was completed with FlowJo software.

ASCs (P4-P7) were seeded onto ncl-PADM and cell obtained viability was using Live/Dead Viability/Cytotoxicity Kit. Cell adhesion on ncl-PADM was assessed using MTT (3-(4, 5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)-assay for 40 minutes to 4 hour. Cell attachment and morphology was examined using SEM at 1 h, 4 h and 24 h after plating. ASC proliferation was also analyzed using MTT assay for 1-14 days. To analyze & optimize the effect of ASCs seeding density on ncl-PADM, cell adhesions on ncl-PADM seeded at 3 initial seeding densities including 25,000, 50,000 and 100,000 cells/cm<sup>2</sup> was compared using MTTassay.

## **Results:**

Flow cytometry results revealed that 99% of cultured cells were CD 29<sup>+</sup>, CD 44<sup>+</sup> and CD 90<sup>+</sup> (Fig 1). ASCs cultured on ncl-PADM for 2 hours stained 99% positive for Calcein live cell staining. SEM pictures demonstrated initial stages of cellular attachment with round morphology (Fig 2) 1 h after plating where as the cell attachment was well established with flat morphology after 4 h incubation. MTT data for initial cell adhesion from 40 min to 4 hours at all initial cell seeding densities including 25,000, 50,000 and 100,000 cells/cm<sup>2</sup> showed a maximum adhesion of 8400 cells/cm<sup>2</sup> (±3400), 13900 cells/cm<sup>2</sup> ( $\pm 15500$ ) and 14353 cells/cm<sup>2</sup> ( $\pm 7849$ ) respectively cells proliferated from 1 day to 14 days on ncl-PADM. A comparison of MTT data for 1 day ASCs culture on ncl-PADM with 25,000 cells/cm<sup>2</sup> and 50,000 cells/cm<sup>2</sup> showed only 6500 cells/cm<sup>2</sup> (±750) and 9300

cells/cm<sup>2</sup> ( $\pm$ 1500). MTT data showed no significant Proliferation of ASC on ncl-PADM within 1 week with a maximum of 7000 cells/cm<sup>2</sup>.



#### **Conclusions:**

Ncl-PADM provides a suitable scaffold for ASCs to adhere and may be useful for clinical reconstructive applications. The optimum seeding density for cell study would be 10,000 cells/cm<sup>2</sup>. In future projects we will evaluate the outcomes of ncl-PADM/ASC constructs for ventral hernia repairs. Mechanical properties, ASC differentiation pattern, growth factor stimulation and histological appearance will be compared to control ncl-PADM repairs to establish potential benefits of ASCbased bioprosthetic mesh for reconstructive surgical applications.

## **References:**

1. Burns NK et al; Plast Reconst Surg 2010; 125(1):167-176

- 2. Butler CE et al; J. Amer. Col. Surgeons 2010;
- 211(3):368-376
- 3. Altman AM et al; Plast Reconst Surg 2010; 126(3): 845-854

#### **Disclosure:**

Dr. Butler serves as a consultant for LifeCell.